Optellum, Johnson & Johnson Collaborate on AI-Powered Lung-Health Initiative

This announcement accelerates Optellum's market entry, building on its FDA clearance earlier this year and deployments underway at hospitals in the USA and ongoing clinical trials in the United Kingdom. It identifies and tracks at-risk patients and assigns a Lung Cancer Prediction score to lung nodules: small lesions, frequently detected in chest Computed Tomography (CT) scans that may or may not be cancerous. The Optellum AI will be used to drive accurate early diagnosis and optimal treatment decisions with the aim of treating patients earlier, potentially at a pre-cancerous stage, increasing survival rates.